Driving cost factors in adult outpatients with refractory epilepsy: A daily clinical practice in clinics of neurology in Spain

Epilepsy Research

Volumn 83, Issue 2-3, 2009, Pages 133-143

  Peña, Pilar ^b   Sancho, Jerónimo ^a   Rufo, Miguel ^c   Martínez, Silvia ^d   Rejas, Javier ^e  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d European Biometrics Institute   (Spain)

^e PFIZER INC   (United States)

Author keywords

Costs; Health resources; LINCE study; Patient reported outcomes; Quality of life; Refractory epilepsy

Indexed keywords

ANTICONVULSIVE AGENT;

ADULT; ANTICONVULSANT THERAPY; ANXIETY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST OF ILLNESS; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE SEVERITY; EPILEPSY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGY; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REFRACTORY EPILEPSY; RESOURCE ALLOCATION; SELF CONCEPT; SPAIN;

ADULT; AMBULATORY CARE; COSTS AND COST ANALYSIS; CROSS-SECTIONAL STUDIES; EPILEPSY; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NEUROLOGY; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SELF CONCEPT; SPAIN;

EID: 58849101207     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2008.10.004     Document Type: Article

References (57)

1. Argumosa A., and Herranz J.L. Economic costs of childhood epilepsy in Spain. Rev. Neurol. 30 (2000) 104-108
2. Arroyo S., Brodie M.J., Avanzini G., Baumgartner C., Chiron C., Dulac O., French J.A., and Serratosa J.M. Is refractory epilepsy preventable?. Epilepsia 43 (2002) 437-444
3. Atkinson M.J., Kumar R., Cappelleri J.C., and Hass S.L. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health 1 Suppl. 8 (2005) S9-S24
4. Badia X., Roset M., Montserrat S., Herdman M., and Segura A. The Spanish version of EuroQol: a description and its applications European Quality of Life scale. Med. Clin. (Barc.) 112 Suppl 1 (1999) 79-85
5. Bautista R.E., Glen E.T., and Shetty N.K. Factors associated with satisfaction with care among patients with epilepsy. Epilepsy Behav. 11 (2007) 518-524
6. Bautista R.E., Glen E.T., Wludyka P.S., and Shetty N.K. Factors associated with utilization of healthcare resources among epilepsy patients. Epilepsy Res. 79 (2008) 120-129
7. Beghi E., Garattini L., Ricci E., Cornago D., and Parazzini F. Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia 45 (2004) 171-178
8. Begley C.E., Famulari M., Annegers J.F., Lairson D.R., Reynolds T.F., Coan S., Dubinsky S., Newmark M.E., Leibson C., So E.L., and Rocca W.A. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 41 (2000) 342-351
9. Berg A.T., and Kelly M.M. Defining intractability: comparisons among published definitions. Epilepsia 47 (2006) 431-436
10. Berg A.T., Vickrey B.G., Testa F.M., Levy S.R., Shinnar S., DiMario F., and Smith S. How long does it take for epilepsy to become intractable? A prospective investigation. Ann. Neurol. 60 (2003) 73-79
11. Birbeck G.L., Hays R.D., Cui X., and Vickrey B.G. Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia 43 (2002) 535-538
12. Boylan L.S., Flint L.A., Labovitz D.L., Jackson S.C., Starner K., and Devinsky O. Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy. Neurology 62 (2004) 258-261
13. Brodie M.J. Diagnosing and predicting refractory epilepsy. Acta Neurol. Scand. Suppl. 181 (2005) 36-39
14. Brodie M.J., Shorvon S.D., Canger R., Halasz P., Johannessen S., Thompson P., Wieser H.G., and Wolf P. Commission on European Affairs: appropriate standards of epilepsy care across Europe.ILEA. Epilepsia 38 (1997) 1245-1250
15. Catálogo de Especialidades Farmacéuticas de, 2005. Consejo General de Colegios Oficiales de Farmacéuticos de España. Madrid, 2005.
16. Cockerell O.C., Hart Y.M., Sander J.W., and Shorvon S.D. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res. 18 (1994) 249-260
17. Cockerell O.C., Johnson A.L., Sander J.W., Hart Y.M., and Shorvon S.D. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 346 (1995) 140-144
18. Collaborative Group for the Study of Epilepsy. Prognosis of epilepsy in newly referred patients: a multicenter prospective study of the effects of monotherapy on the long-term course of epilepsy. Epilepsia 33 (1992) 45-51
19. Cramer J.A. A clinimetric approach to assessing quality of life in epilepsy. Epilepsia 34 Suppl. 4 (1993) S8-13
20. Cramer J.A., Perrine K., Devinsky O., and Meador K. A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10. Epilepsia 37 (1996) 577-582
21. Cramer J.A., Brandenburg N., and Xu X. Differentiating anxiety and depression symptoms in patients with partial epilepsy. Epilepsy Behav. 6 (2005) 563-569
22. De la Pena Mayor P., Saiz Diaz R.A., Perez-Sempere A., Sancho J., Cobaleda S., and Padro Ubeda L. Quality of the health care to the epileptic patients in Spain. Neurologia 20 (2005) 332-340
23. Devinsky O., and Penry J.K. Quality of life in epilepsy: the clinician's view. Epilepsia 34 Suppl. 4 (1993) S4-7
24. Doughty J., Baker G.A., Jacoby A., and Lavaud V. Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsy. Epilepsy Behav. 4 (2003) 710-716
25. Forsgren I., Beghi E., and Ekman M. Cost of epilepsy in Europe. Eur. J. Neurol. 1 Suppl. 12 (2005) 54-58
26. French J.A., Kanner A.M., Bautista J., Abou-Khalil B., Browne T., Harden C.L., Theodore W.H., Bazil C., Stern J., Schachter S.C., Bergen D., Hirtz D., Montouris G.D., Nespeca M., Gidal B., Marks Jr. W.J., Turk W.R., Fischer J.H., Bourgeois B., Wilner A., Faught Jr. R.E., Sachdeo R.C., Beydoun A., and Glauser T.A. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62 (2004) 1261-1273
27. Gisbert R., and Brosa M. Base de datos de costes sanitarios version 2. 2 (2005), Instituto Soikos, Barcelona
28. Gomez-Alonso J., and Giraldez B.G. Epilepsy: a new definition for an old disease. Rev. Neurol. 45 (2007) 126-127
29. Hamer H.M., Spottke A., Aletsee C., Knake S., Reis J., Strzelczyk A., Oertel W.H., Rosenow F., and Dodel R. Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany. Epilepsia 47 (2006) 2165-2172
30. Heaney D.C., Sander J.W., and Shorvon S.D. Comparing the cost of epilepsy across eight European countries. Epilepsy Res. 43 (2001) 89-95
31. Jacoby A., Buck D., Baker G., McNamee P., Graham-Jones S., and Chadwick D. Uptake and costs of care for epilepsy: findings from a U.K. regional study. Epilepsia 39 (1998) 776-786
32. Kanner A.M. Epilepsy and mood disorders. Epilepsia 48 Suppl. 9 (2007) 20-22
33. Kotsopoulos I.A., van Merode T., Kessels F.G., de Krom M.C., and Knottnerus J.A. Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia 43 (2002) 1402-1409
34. Kwan P., and Sander J.W. The natural history of epilepsy: an epidemiological view. J. Neurol. Neurosurg. Psychiatry 75 (2004) 1376-1381
35. Langfitt J.T., Vickrey B.G., McDermott M.P., Messing S., Berg A.T., Spencer S.S., Sperling M.R., Bazil C.W., and Shinnar S. Validity and responsiveness of generic preference-based HRQOL instruments in chronic epilepsy. Qual. Life Res. 15 (2006) 899-914
36. Likert R. A technique for the measurement of attitudes. Arch. Psychol. 140 (1932) 1-55
37. Lindsten H., Stenlund H., and Forsgren L. Remission of seizures in a population-based adult cohort with a newly diagnosed unprovoked epileptic seizure. Epilepsia 42 (2001) 1025-1030
38. Murray M.I., Halpern M.T., and Leppik I.E. Cost of refractory epilepsy in adults in the USA. Epilepsy Res. 23 (1996) 139-148
39. Naess S., Eriksen J., and Tambs K. Psychological well-being of people with epilepsy in Norway. Epilepsy Behav. 11 (2007) 310-315
40. Pato-Pato A., Cimas-Hernando I., Lorenzo-Gonzalez J.R., and Vadillo-Olmo F.J. The economic impact of epilepsy. Rev. Neurol. 39 (2004) 450-453
41. Perini G., and Mendius R. Depression and anxiety in complex partial seizures. J. Nerv. Ment. Dis. 172 (1984) 287-290
42. Perucca E., and Meador K.J. Adverse effects of antiepileptic drugs. Acta Neurol. Scand. Suppl. 181 (2005) 30-35
43. Rufo-Campos R., Sancho-Rieger J., Peña P., Masramon X., Rejas-Gutiérrez J. en nombre del grupo de colaboradores del estudio LINCE, 2008. Pautas terapéuticas en el paciente con epilepsia farmacorresistente en consultas ambulatorias de neurología y epilepsia en España. Rev Neurol 47, 517-524.
44. © Value Health 11 (2008) 913-926
45. Sabaz M., Cairns D.R., Lawson J.A., Bleasel A.F., and Bye A.M. The health-related quality of life of children with refractory epilepsy: a comparison of those with and without intellectual disability. Epilepsia 42 (2001) 621-628
46. Saíz Díaz R. Antiepilépticos: aportación de los nuevos fármacos. Inf. Ter. Sist. Nac. Salud. 28 (2004) 33-40
47. Sanchez-Alvarez J.C., Serrano-Castro P., and Canadillas-Hidalgo F. Refractory epilepsy in adults. Rev. Neurol. 35 (2002) 931-953
48. Sancho J., Peña P., Rufo M., Palacios G., Masramon X., and Rejas J. LINCE study collaborative group. Health and Non-Health Care resources use in the management of adult outpatients with drug-resistant epilepsy in Spain: a cost-of-illness study (LINCE study). Epilepsy Res 81 (2008) 176-187
49. Schachter S.C. Epilepsy: quality of life and cost of care. Epilepsy Behav. 1 (2000) 120-127
50. Shikiar R., and Rentz A.M. Satisfaction with medication: an overview of conceptual, methodologic, and regulatory issues. Value Health 7 (2004) 204-215
51. Smeets V.M., van Lierop B.A., Vanhoutvin J.P., Aldenkamp A.P., and Nijhuis F.J. Epilepsy and employment: literature review. Epilepsy Behav. 10 (2007) 354-362
52. Smith D.B., Craft B.R., Collins J., Mattson R.H., and Cramer J.A. Behavioral characteristics of epilepsy patients compared with normal controls. Epilepsia 27 (1986) 760-768
53. Tetto A., Manzoni P., Millul A., Beghi E., Garattini L., Tartara A., and Avanzini G. The costs of epilepsy in Italy: a prospective cost-of-illness study in referral patients with disease of different severity. Epilepsy Res. 48 (2002) 207-216
54. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16 3 (1990) 199-208
55. Uijl S.G., Uiterwaal C.S., Aldenkamp A.P., Carpay J.A., Doelman J.C., Keizer K., Vecht C.J., de Krom M.C., and van Donselaar C.A. A cross-sectional study of subjective complaints in patients with epilepsy who seem to be well-controlled with anti-epileptic drugs. Seizure 15 (2006) 242-248
56. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects, 2002. J. Postgrad. Med. 48, 206-208.
57. Zigmond A.S., and Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 67 (1983) 361-370